Esmaeil Sebti
Neurology · Yucca Valley, CANPI 1194728881
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,858 of the $15,034 with a category attached, or 85.5%. 44 manufacturers reported payments, led by UCB, Inc. at 27.0% of the total. Reporting peaked in 2024 at $3,625 and has fallen 52.8% since, to $1,711 in 2025.
Across 316 payments — averaging $47.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$4K
- AbbVie$2K
- Neurocrine Biosciences, Inc.$1K
- Biogen$829
- AstraZeneca$827
- MDD US Operations, LLC$410
- plus $6K from 38 others
What the payments were for
- Consulting fees$2,13014%
- Speaking & faculty fees$460%
- Food & beverage$12,85886%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,034 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UltomirisRavulizumab-Cwvz | 12 | $819,224 |
| Sapropterin Dihydrochloride | 15 | $146,549 |
| Aimovig AutoinjectorErenumab-Aooe | 68 | $57,350 |
| Nurtec OdtRimegepant Sulfate | 30 | $39,542 |
| UbrelvyUbrogepant | 25 | $26,443 |
| QuliptaAtogepant | 14 | $25,339 |
| RytaryCarbidopa/Levodopa | 12 | $9,484 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 242 | $8,168 |
| Levetiracetam | 157 | $3,788 |
| Carbamazepine ErCarbamazepine | 27 | $2,653 |
| Modafinil | 13 | $2,420 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 56 | $2,162 |
| Lamotrigine | 154 | $1,957 |
| Lacosamide | 20 | $1,821 |
| Gabapentin | 102 | $1,740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaUltomiris | $827 | $819,22412 claims |
| AbbVieUbrelvy, Qulipta | $1,795 | $51,78139 claims |
| PfizerNurtec Odt | $65 | $39,54230 claims |
| Amneal Pharmaceuticals LLCRytary | $223 | $9,48412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,996 neurology providers in California.
Other neurology in Yucca Valley
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
- Benjamin FrishbergCarlsbad$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.